The pathogenesis of COPD: Lessons learned from in vivo animal models

Masaki Fujita, Yoichi Nakanishi

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitations, that are not fully reversible. COPD is a major cause of chronic morbidity and mortality throughout the world. Tobacco smoking is a most important risk factor for the development of COPD. However, only 10 to 20% smokers develop clinically significant COPD. The detailed pathogenesis also remains to be elucidated. In vivo animal models provided some clues to help clarify the pathogenesis. Several important factors such as matrix metalloproteinases, apoptosis, protease-antiprotease imbalance, are considered to contribute to the development of COPD. In addition to these factors, chronic inflammation affects lung morphogenesis and causes several pathological involvements including COPD. In this article, we review the pathogenesis of COPD, while especially focusing on the recent advances and the effects of chronic inflammation using an in vivo animal model. This article aims at offering valuable information for both proceeding with COPD research as well as for developing a new medicines for the treatment of COPD.

Original languageEnglish
Pages (from-to)RA19-RA24
JournalMedical Science Monitor
Volume13
Issue number2
Publication statusPublished - Feb 1 2007

Fingerprint

Chronic Obstructive Pulmonary Disease
Animal Models
Protease Inhibitors
Matrix Metalloproteinases
Morphogenesis
Pneumonia
Peptide Hydrolases
Smoking
Apoptosis
Inflammation
Morbidity
Mortality
Research

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

The pathogenesis of COPD : Lessons learned from in vivo animal models. / Fujita, Masaki; Nakanishi, Yoichi.

In: Medical Science Monitor, Vol. 13, No. 2, 01.02.2007, p. RA19-RA24.

Research output: Contribution to journalReview article

Fujita, M & Nakanishi, Y 2007, 'The pathogenesis of COPD: Lessons learned from in vivo animal models', Medical Science Monitor, vol. 13, no. 2, pp. RA19-RA24.
Fujita, Masaki ; Nakanishi, Yoichi. / The pathogenesis of COPD : Lessons learned from in vivo animal models. In: Medical Science Monitor. 2007 ; Vol. 13, No. 2. pp. RA19-RA24.
@article{be160aafe8c94a4d942769f538188199,
title = "The pathogenesis of COPD: Lessons learned from in vivo animal models",
abstract = "Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitations, that are not fully reversible. COPD is a major cause of chronic morbidity and mortality throughout the world. Tobacco smoking is a most important risk factor for the development of COPD. However, only 10 to 20{\%} smokers develop clinically significant COPD. The detailed pathogenesis also remains to be elucidated. In vivo animal models provided some clues to help clarify the pathogenesis. Several important factors such as matrix metalloproteinases, apoptosis, protease-antiprotease imbalance, are considered to contribute to the development of COPD. In addition to these factors, chronic inflammation affects lung morphogenesis and causes several pathological involvements including COPD. In this article, we review the pathogenesis of COPD, while especially focusing on the recent advances and the effects of chronic inflammation using an in vivo animal model. This article aims at offering valuable information for both proceeding with COPD research as well as for developing a new medicines for the treatment of COPD.",
author = "Masaki Fujita and Yoichi Nakanishi",
year = "2007",
month = "2",
day = "1",
language = "English",
volume = "13",
pages = "RA19--RA24",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",
number = "2",

}

TY - JOUR

T1 - The pathogenesis of COPD

T2 - Lessons learned from in vivo animal models

AU - Fujita, Masaki

AU - Nakanishi, Yoichi

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitations, that are not fully reversible. COPD is a major cause of chronic morbidity and mortality throughout the world. Tobacco smoking is a most important risk factor for the development of COPD. However, only 10 to 20% smokers develop clinically significant COPD. The detailed pathogenesis also remains to be elucidated. In vivo animal models provided some clues to help clarify the pathogenesis. Several important factors such as matrix metalloproteinases, apoptosis, protease-antiprotease imbalance, are considered to contribute to the development of COPD. In addition to these factors, chronic inflammation affects lung morphogenesis and causes several pathological involvements including COPD. In this article, we review the pathogenesis of COPD, while especially focusing on the recent advances and the effects of chronic inflammation using an in vivo animal model. This article aims at offering valuable information for both proceeding with COPD research as well as for developing a new medicines for the treatment of COPD.

AB - Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitations, that are not fully reversible. COPD is a major cause of chronic morbidity and mortality throughout the world. Tobacco smoking is a most important risk factor for the development of COPD. However, only 10 to 20% smokers develop clinically significant COPD. The detailed pathogenesis also remains to be elucidated. In vivo animal models provided some clues to help clarify the pathogenesis. Several important factors such as matrix metalloproteinases, apoptosis, protease-antiprotease imbalance, are considered to contribute to the development of COPD. In addition to these factors, chronic inflammation affects lung morphogenesis and causes several pathological involvements including COPD. In this article, we review the pathogenesis of COPD, while especially focusing on the recent advances and the effects of chronic inflammation using an in vivo animal model. This article aims at offering valuable information for both proceeding with COPD research as well as for developing a new medicines for the treatment of COPD.

UR - http://www.scopus.com/inward/record.url?scp=33846926830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846926830&partnerID=8YFLogxK

M3 - Review article

C2 - 17261992

AN - SCOPUS:33846926830

VL - 13

SP - RA19-RA24

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

IS - 2

ER -